Anlotinib Plus Docetaxel

DRUG2 trials

Sponsors

Hunan Cancer Hospital, First Affiliated Hospital of Guangxi Medical University

Conditions

Non-small Cell Lung Cancer

Phase 2

Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer

Hunan Cancer HospitalNon-small Cell Lung Cancer

Start: 2018-10-15End: 2020-12-31Target: 84Updated: 2020-01-07

Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

First Affiliated Hospital of Guangxi Medical UniversityNon-small Cell Lung Cancer

Start: 2018-10-01End: 2020-10-01Target: 84Updated: 2018-08-31

Related Papers

Anlotinib Plus Docetaxel is Promising in Advanced NSCLC Progressing on First-Line Immunotherapy: A Pooled Analysis of Two Randomized Trials.

2025-05-12

Anlotinib plus docetaxel in advanced NSCLC progressing on immunotherapy: A pooled analysis of two randomized trials.

Journal of Clinical Oncology2024-06-011 citations

A multicenter, randomized, phase II trial of anlotinib plus docetaxel versus docetaxel in EGFR-negative NSCLC patients after progression on first-line platinum-base chemotherapy: ALTER-L018.

Journal of Clinical Oncology2021-05-20

A randomized phase II multi-institutional trial of anlotinib plus docetaxel versus docetaxel in EGFR-wild-type non-small cell lung cancer (NSCLC) patients after progression on first-line platinum-base chemotherapy: ALTER-L018.

Journal of Clinical Oncology2020-05-202 citations